Subscribe to RSS
DOI: 10.1055/s-0038-1677531
Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale
Funding The Bridging ITP Trial was funded by Novartis. Program funding for the McMaster Center for Transfusion Research was provided by Canadian Blood Services, the Federal Government of Canada (Health Canada) and Provincial and Territorial Ministries of Health.Publication History
19 June 2018
29 November 2018
Publication Date:
27 January 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/201903/lookinside/thumbnails/10-1055-s-0038-1677531_180440-1.jpg)
Abstract
Background The Bridging ITP Trial is an open-label randomized trial designed to compare the oral thrombopoietin receptor agonist eltrombopag and intravenous immune globulin (IVIG) for patients with immune thrombocytopaenia (ITP) who require an increase in platelet count before elective surgery. Here, we report the study methods and rationale.
Methods We designed a multi-centre, non-inferiority randomized trial comparing daily oral eltrombopag starting 3 weeks pre-operatively, and IVIG administered 1 week pre-operatively for patients with ITP requiring a platelet count increase prior to surgery. Starting dose of eltrombopag is 50 mg daily with a weekly pre-operative dose titration schedule, and treatment is continued for 1 week after surgical haemostasis is achieved. IVIG is administered at a dose of 1 to 2 g/kg 1 week pre-operatively with the allowance for a second dose within 1 week after surgical haemostasis. The objective of the study is to demonstrate non-inferiority of eltrombopag for the primary endpoint of achieving the pre-operative platelet count threshold (50 × 109/L for minor surgery; or 100 × 109/L for major surgery) and sustaining platelet count levels above the threshold for 1 week after surgical haemostasis is achieved, without the use of rescue treatment. Secondary endpoints include thrombosis, bleeding and patient satisfaction.
Conclusion The Bridging ITP Trial will evaluate the efficacy and safety of eltrombopag as an alternative to IVIG in the peri-operative setting for patients with ITP. The protocol was designed to provide a management strategy that can be applied in clinical practice.
ClinicalTrials.gov Identifier NCT01621204.
-
References
- 1 Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999; 107 (04) 716-719
- 2 Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apheresis Sci 2012; 46 (01) 93-96
- 3 Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010; 9 (06) 971-979
- 4 Provan D, Stasi R, Newland AC. , et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (02) 168-186
- 5 Bharath V, Eckert K, Kang M, Chin-Yee IH, Hsia CC. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Transfusion 2015; 55 (11) 2597-2605
- 6 Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6 (04) 535-542
- 7 Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122 (06) 1238-1239
- 8 Cherin P, Marie I, Michallet M. , et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev 2016; 15 (01) 71-81
- 9 Mohamed M. Intravenous immunoglobulin-associated hemolysis: risk factors, challenges, and solutions. Int J Clin Transfus Med. 2016; 4: 121-131
- 10 Daniel GW, Menis M, Sridhar G. , et al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 2012; 52 (10) 2113-2121
- 11 Ramírez E, Romero-Garrido JA, López-Granados E. , et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res 2014; 133 (06) 1045-1051
- 12 Chow S, Salmasi G, Callum JL, Lin Y. Trimming the fat with an IVIG approval process. Transfus Apheresis Sci 2012; 46 (03) 349-352
- 13 Hsia CC, Liu Y, Eckert K, Monga N, Elia-Pacitti J, Heddle NM. Intravenous immunoglobulin (IVIg) utilization in immune thrombocytopenia (ITP): a multi-center, retrospective review. Drugs Real World Outcomes 2015; 2 (01) 35-42
- 14 Bussel JB, Provan D, Shamsi T. , et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373 (9664): 641-648
- 15 Cheng G, Saleh MN, Marcher C. , et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377 (9763): 393-402
- 16 Wong RSM, Saleh MN, Khelif A. , et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017; 130 (23) 2527-2536
- 17 Rodeghiero F. Is ITP a thrombophilic disorder?. Am J Hematol 2016; 91 (01) 39-45
- 18 Knuth D. The Art of Computer Programming, Volume 2: Seminumerical Algorithms. 3rd ed. Reading, MA: Addison-Wesley; 1997
- 19 Novartis Pharmaceuticals Inc. Revolade Product Monograph [Internet]. 2015 . Available at: https://www.novartis.ca/sites/www.novartis.ca/files/revolade_scrip_e.pdf . Accessed April 2, 2018
- 20 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. ; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
- 21 Page LK, Psaila B, Provan D. , et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 2007; 138 (02) 245-248
- 22 Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8 (Suppl. 01) S9-S24
- 23 Kuter DJ, Rummel M, Boccia R. , et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363 (20) 1889-1899
- 24 Lawless J. Event history analysis and longitudinal surveys. In: Chambers R, Skinner C, eds. Analysis of Survey Data. Chichester, West Sussex: John Wiley & Sons, Ltd; 2003: 221-243
- 25 Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 2018; 181 (02) 183-195
- 26 British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120 (04) 574-596
- 27 Estcourt LJ, Birchall J, Allard S. , et al; British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2017; 176 (03) 365-394
- 28 Marshall AL, Goodarzi K, Kuter DJ. Romiplostim in the management of the thrombocytopenic surgical patient. Transfusion 2015; 55 (10) 2505-2510
- 29 Ramakrishna R, Rehman A, Ramakrishna S, Alexander W, Yeo WW. Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period. Intern Med J 2015; 45 (07) 718-724
- 30 Zaja F, Barcellini W, Cantoni S. , et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Am J Hematol 2016; 91 (05) E293-E295
- 31 Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol 2018; 182 (01) 106-113
- 32 Kolb JM, Kaltenbach T, Martin B, Rouse RV, Soetikno R. Eltrombopag use in thrombocytopenia for endoscopic submucosal dissection of a gastric carcinoid. ACG Case Rep J 2014; 2 (01) 24-26
- 33 Shomura S, Katayama Y, Kusagawa H, Komada T. Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery [in Japanese]. Kyobu Geka 2014; 67 (03) 203-206
- 34 Landete E, Domingo A, Pérez-Rus G. , et al. Perioperative use of eltrombopag in patients with chronic thrombocytopenia. A single-centre experience. 23rd Congress of the European Hematology Association; June 14–17, 2018 ; Stockholm, Sweden
- 35 Tarantino MD, Fogarty PF, Shah P, Brainsky A. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Platelets 2015; 26 (01) 93-96
- 36 Tarantino MD, Bakshi KK, Brainsky A. Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag. Platelets 2014; 25 (01) 55-61
- 37 Bussel JB, Eldor A, Kelton JG. , et al; IGIV-C in ITP Study Group. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004; 91 (04) 771-778
- 38 Godeau B, Chevret S, Varet B. , et al; French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002; 359 (9300): 23-29
- 39 Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res 2010; 89 (03) 219-229